Intox Private Limited

Intox Private Limited is a specialized toxicology testing service provider, focusing on comprehensive safety assessments for pharmaceuticals, biopharmaceuticals, and various chemicals, ensuring compliance with global regulatory standards. Founded in 1995 and headquartered in Pune, India, Intox Private Limited offers toxicology testing services. The company was acquired by Aragen Life Sciences Pvt. Ltd.

in December 2021, enhancing its operational capabilities. Narendra Deshmukh, the founder, has a history in the industry, contributing to the company's development of specialized services. Intox, as a subsidiary of Aragen Life Sciences, provides a wide range of toxicology testing services for both clinical and non-clinical applications. Their offerings include safety assessment studies for pharmaceuticals, biopharmaceuticals, vaccines, and other compounds, utilizing GLP and non-GLP research methodologies.

The company's advanced analytical chemistry techniques enable rigorous testing for impurity profiling and physicochemical characterization, serving clients across North America, Europe, and Asia-Pacific. In 2022, Intox reported a revenue of USD 8. 72 mn and an EBITDA of USD 3. 27 mn.

The company’s revenue is primarily generated through B2B collaborations with pharmaceutical companies and manufacturers requiring specialized toxicology assessments, structured around comprehensive service contracts. Following its acquisition in December 2021, Intox aims to expand its geographic footprint across India, leveraging Aragen Life Sciences' resources for conducting safety assessment studies from its GLP-certified facilities. The recent acquisition will facilitate the launch of new toxicology services tailored to emerging markets in Asia by 2024, enhancing the company’s market reach and service portfolio.